Development of AD214 a novel anti-fibrotic treatment for advanced Age related macular degeneration

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/2000044

Funding Status
Status not available

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Age related macular degeneration remains the leading cause of blindness in this and other industrialised countries. Although treatment is available for an advanced form of the disease, many do not respond, or lose significant amounts of vision with long term treatment. This proposal will provide critical data for commericalizing a novel therapy called an i-body (AD214), that reduces vision loss in this disease by blocking the formation of scarring with reduced need for injections.

Funded Activity Details

Start Date: 01-01-2020

End Date: End date not available

Funding Scheme: Development Grants

Funding Amount: $687,994.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

animal model | antibody therapy | macular degeneration | pharmaceutical treatment

Related Links